Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients

Stroke

Volumn 47, Issue 11, 2016, Pages 2805-2812

  Qin, Xianhui ^a   Li, Jianping ^b   Spence, J David ^c   Zhang, Yan ^b   Li, Youbao ^a   Wang, Xiaobin ^d   Wang, Binyan ^a   Sun, Ningling ^e   Chen, Fang ^f   Guo, Jingxuan ^b   Yin, Delu ^g   Sun, Liming ^h   Tang, Genfu ⁱ   He, Mingli ^g   Fu, Jia ⁱ   Cai, Yefeng ^j   Shi, Xiuli ⁱ   Ye, Ping ^k   Chen, Hong ^e   Zhao, Shuiping ^l   Chen, Mao ^m   Gao, Chuanyu ⁿ   Kong, Xiangqing ^o   Hou, Fan Fan ^a   Huang, Yining ^b   Huo, Yong ^b   more..

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b PEKING UNIVERSITY   (China)

^c ROBARTS RESEARCH INSTITUTE   (Canada)

^d JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^e PEKING UNIVERSITY PEOPLE S HOSPITAL   (China)

^f CAPITAL MEDICAL UNIVERSITY   (China)

^g The First People's Hospital   (China)

^h Second People's Hospital   (China)

ⁱ ANHUI MEDICAL UNIVERSITY   (China)

^j GUANGDONG PROVINCIAL HOSPITAL OF CHINESE MEDICINE   (China)

^k CHINESE PLA GENERAL HOSPITAL   (China)

^l CENTRAL SOUTH UNIVERSITY   (China)

^m SICHUAN UNIVERSITY   (China)

ⁿ ZHENGZHOU UNIVERSITY   (China)

^o NANJING MEDICAL UNIVERSITY   (China)

more..

Author keywords

cholesterol; folic acid; hypercholesterolemia; risk factors; stroke

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIDIABETIC AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; ENALAPRIL; FOLIC ACID; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ANTIHYPERTENSIVE AGENT; VITAMIN B COMPLEX;

ADULT; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR MORTALITY; CEREBROVASCULAR ACCIDENT; CHOLESTEROL BLOOD LEVEL; CLINICAL OUTCOME; CONFIDENCE INTERVAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; FEMALE; FOLIC ACID BLOOD LEVEL; HAZARD RATIO; HEART INFARCTION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; STROKE RISK; SYSTOLIC BLOOD PRESSURE; TREATMENT DURATION; VITAMIN SUPPLEMENTATION; AGED; BLOOD; CHINA; COMBINATION DRUG THERAPY; COMORBIDITY; RISK; STROKE;

AGED; ANTIHYPERTENSIVE AGENTS; CHINA; COMORBIDITY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ENALAPRIL; FEMALE; FOLIC ACID; HUMANS; HYPERCHOLESTEROLEMIA; HYPERTENSION; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); RISK; STROKE; VITAMIN B COMPLEX;

EID: 84992752981     PISSN: 00392499     EISSN: 15244628     Source Type: Journal    
DOI: 10.1161/STROKEAHA.116.014578     Document Type: Article

References (25)

1. Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E; Heart Outcomes Prevention Evaluation 2 Investigators. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial. Stroke. 2009;40:1365-1372. doi: 10.1161/STROKEAHA.108.529503.
2. Huo Y, Qin X, Wang J, Sun N, Zeng Q, Xu X, et al. Efficacy of folic acid supplementation in stroke prevention: new insight from a meta-Analysis. Int J Clin Pract. 2012;66:544-551. doi: 10.1111/j.1742-1241.2012.02929.x.
3. Pezzini A, Grassi M, Del Zotto E, Assanelli D, Archetti S, Negrini R, et al. Interaction of homocysteine and conventional predisposing factors on risk of ischaemic stroke in young people: consistency in phenotypedisease analysis and genotype-disease analysis. J Neurol Neurosurg Psychiatry. 2006;77:1150-1156. doi: 10.1136/jnnp.2005.076083.
4. Graham IM, Daly LE, Refsum HM, Robinson K, Brattström LE, Ueland PM, et al. Plasma homocysteine as a risk factor for vascular disease. The European Concerted Action Project. JAMA. 1997;277:1775-1781.
5. Huo Y, Li J, Qin X, Huang Y, Wang X, Gottesman RF, et al; CSPPT Investigators. Efficacy of folic acid therapy in primary prevention of stroke among adults with hypertension in China: the CSPPT randomized clinical trial. JAMA. 2015;313:1325-1335. doi: 10.1001/jama.2015.2274.
6. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the NCEP Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation.2002;106:3143-3421.
7. Bhatt DL, Steg PG, Ohman EM, Hirsch AT, Ikeda Y, Mas JL, et al; REACH Registry Investigators. International prevalence, recognition, and treatment of cardiovascular risk factors in outpatients with atherothrombosis. JAMA. 2006;295:180-189. doi: 10.1001/jama.295.2.180.
8. Mozaffarian D, Benjamin EJ, Go AS, Arnett DK, Blaha MJ, Cushman M, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2015 update: a report from the American Heart Association. Circulation. 2015;131:e29-e322. doi: 10.1161/CIR.0000000000000152.
9. He J, Gu D, Reynolds K, Wu X, Muntner P, Zhao J, et al; InterASIA Collaborative Group. Serum total and lipoprotein cholesterol levels and awareness, treatment, and control of hypercholesterolemia in China. Circulation. 2004;110:405-411. doi: 10.1161/01. CIR.0000136583.52681.0D.
10. Yusuf S, Bosch J, Dagenais G, Zhu J, Xavier D, Liu L, et al; HOPE-3 Investigators. Cholesterol lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2021-2031. doi: 10.1056/NEJMoa1600176.
11. Banach M, Rizzo M, Toth PP, Farnier M, Davidson MH, Al-Rasadi K, et al. Statin intolerance-An attempt at a unified definition. Position paper from an International Lipid Expert Panel. Expert Opin Drug Saf. 2015;14:935-955. doi: 10.1517/14740338.2015.1039980.
12. Sathasivam S. Statin induced myotoxicity. Eur J Intern Med. 2012;23:317-324. doi: 10.1016/j.ejim.2012.01.004.
13. Culver AL, Ockene IS, Balasubramanian R, Olendzki BC, Sepavich DM, Wactawski-Wende J, et al. Statin use and risk of diabetes mellitus in postmenopausal women in the Women's Health Initiative. Arch Intern Med. 2012;172:144-152. doi: 10.1001/archinternmed.2011.625.
14. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45:3754-3832. doi: 10.1161/STR.0000000000000046.
15. Yusuf S, Islam S, Chow CK, Rangarajan S, Dagenais G, Diaz R, et al; Prospective Urban Rural Epidemiology (PURE) Study Investigators. Use of secondary prevention drugs for cardiovascular disease in the community in high-income, middle-income, and low-income countries (the PURE Study): a prospective epidemiological survey. Lancet. 2011;378:1231-1243. doi: 10.1016/S0140-6736(11)61215-4.
16. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217-223. doi: 10.1016/S0140-6736(05)17741-1.
17. Wang J, Zhang L, Wang F, Liu L, Wang H; China National Survey of Chronic Kidney Disease Working Group. Prevalence, awareness, treatment, and control of hypertension in China: results from a national survey. Am J Hypertens. 2014;27:1355-1361. doi: 10.1093/ajh/hpu053.
18. Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al; American College of Cardiology/American Heart Association Task Force on Practice Guidelines. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;63(25 pt B):2889-2934. doi: 10.1016/j.jacc.2013.11.002.
19. Ouweneel AB, Van Eck M. Lipoproteins as modulators of atherothrombosis: from endothelial function to primary and secondary coagulation. Vascul Pharmacol. 2016;82:1-10. doi: 10.1016/j.vph.2015.10.009.
20. Moens AL, Vrints CJ, Claeys MJ, Timmermans JP, Champion HC, Kass DA. Mechanisms and potential therapeutic targets for folic acid in cardiovascular disease. Am J Physiol Heart Circ Physiol. 2008;294:H1971-H1977. doi: 10.1152/ajpheart.91503.2007.
21. Verhaar MC, Stroes E, Rabelink TJ. Folates and cardiovascular disease. Arterioscler Thromb Vasc Biol. 2002;22:6-13.
22. Amarenco P, Lavallee P, Touboul PJ. Stroke prevention, blood cholesterol, and statins. Lancet Neurol. 2004;3:271-278. doi: 10.1016/S1474-4422(04)00734-3.
23. Bailey RL, Dodd KW, Gahche JJ, Dwyer JT, McDowell MA, Yetley EA, et al. Total folate and folic acid intake from foods and dietary supplements in the United States: 2003-2006. Am J Clin Nutr. 2010;91:231-237. doi: 10.3945/ajcn.2009.28427.
24. Pfeiffer CM, Johnson CL, Jain RB, Yetley EA, Picciano MF, Rader JI, et al. Trends in blood folate and vitamin B-12 concentrations in the United States, 1988 2004. Am J Clin Nutr. 2007;86:718-727.
25. VITATOPS Trial Study Group. Antiplatelet therapy and the effects of B vitamins in patients with previous stroke or transient ischemic attack: a post-hoc subanalysis of VITATOPS, a randomized, placebo-controlled trial. Lancet Neurol. 2012;11:512-520.